PPAR beta/gamma mediates the antihypertensive activity of a synbiotic preparation of

Antihypertensive activity Metabolomics PPAR pathway Proteomics Spontaneous hypertensive rat Synbiotics

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 09 04 2024
revised: 25 07 2024
accepted: 11 08 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: epublish

Résumé

Hypertension is a global public health concern. A synbiotic preparation containing Blood pressure in rats was measured using the tail-cuff method. Colonization of the gastrointestinal tract by the two probiotics was determined by real-time quantitative polymerase chain reaction (qPCR). Mechanistic studies were performed by proteomic analyses based on liquid chromatography-mass spectrometry and STRING database and metabolomic analyses using the UHPLC-Q-TOF/MS platform and peroxisome proliferator-activated receptor (PPAR)β/γ antagonists. Although biochemical analysis of blood samples showed that the synbiotic preparation did not alter the levels of angiotensin II, aldosterone, or cortisol, it significantly lowered the systolic blood pressure in the treatment group. Moreover, the synbiotic preparation contributed to the localization of the two probiotics in the ileum and colon of the treatment group. Proteomics, immunochemistry, and real-time qPCR analyses showed that administration of the synbiotic preparation activated the PPAR signaling pathway in the ileum and significantly upregulated PPARβ and PPARγ. The antagonist studies further confirmed this finding. In addition, metabolomic analyses demonstrated that among the 27 metabolites that showed significant differences between the control and model groups, administration of the synbiotic preparation significantly upregulated lysophosphatidylethanolamine and phosphatidylcholine in the ileum of the treatment group. The results of the study suggest that the novel synbiotic preparation reduces blood pressure by altering the composition of the intestinal microbiota, regulating PPAR signaling pathway, and activating the PPARβ and PPARγ cascade reactions in the ileum.

Sections du résumé

Background UNASSIGNED
Hypertension is a global public health concern. A synbiotic preparation containing
Methods and results UNASSIGNED
Blood pressure in rats was measured using the tail-cuff method. Colonization of the gastrointestinal tract by the two probiotics was determined by real-time quantitative polymerase chain reaction (qPCR). Mechanistic studies were performed by proteomic analyses based on liquid chromatography-mass spectrometry and STRING database and metabolomic analyses using the UHPLC-Q-TOF/MS platform and peroxisome proliferator-activated receptor (PPAR)β/γ antagonists. Although biochemical analysis of blood samples showed that the synbiotic preparation did not alter the levels of angiotensin II, aldosterone, or cortisol, it significantly lowered the systolic blood pressure in the treatment group. Moreover, the synbiotic preparation contributed to the localization of the two probiotics in the ileum and colon of the treatment group. Proteomics, immunochemistry, and real-time qPCR analyses showed that administration of the synbiotic preparation activated the PPAR signaling pathway in the ileum and significantly upregulated PPARβ and PPARγ. The antagonist studies further confirmed this finding. In addition, metabolomic analyses demonstrated that among the 27 metabolites that showed significant differences between the control and model groups, administration of the synbiotic preparation significantly upregulated lysophosphatidylethanolamine and phosphatidylcholine in the ileum of the treatment group.
Conclusion UNASSIGNED
The results of the study suggest that the novel synbiotic preparation reduces blood pressure by altering the composition of the intestinal microbiota, regulating PPAR signaling pathway, and activating the PPARβ and PPARγ cascade reactions in the ileum.

Identifiants

pubmed: 39247358
doi: 10.1016/j.heliyon.2024.e36157
pii: S2405-8440(24)12188-3
pmc: PMC11379581
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e36157

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

It is the first time to submit the research article to Heliyon. This manuscript is based on the original research results and has never been published elsewhere. We warrant that all of the authors have contributed substantially to the manuscript and approved the final submission. If accepted, it will not be published elsewhere in the same form, in English or in any other language.

Auteurs

Ying Huang (Y)

Department of Cardiovascular, Liaoning Jin Qiu Hospital, No.317 Xiaonan Street, Shenhe District, Shenyang, Liaoning Province, 110016, China.

Fang Wang (F)

Department of Nursing, General Hospital of Northern Theater Command, No.83 Wenhua Road, Shenhe District, Shenyang, Liaoning Province, 110016, China.

Wei Gong (W)

Department of Food and Drug Inspection, Shenyang Joint Logistics Support Center Drug Instrument Supervision and Inspection Station, 53# Zhonggong Rd, Tiexi District, Shenyang, Liaoning, 110026, China.

Yufeng Chen (Y)

Department of Nuclear Medicine, General Hospital of Northern Theater Command, No.83 Wenhua Road, Shenhe District, Shenyang, Liaoning Province, 110016, China.

Classifications MeSH